Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Martin, L. Ficker, H. Aguilar, S. Gardner, L. Wilson, T. Meredith (1990)
Vitreous cefazolin levels after intravenous injection. Effects of inflammation, repeated antibiotic doses, and surgery.Archives of ophthalmology, 108 3
W. Craig, S. Ebert (1990)
Killing and regrowth of bacteria in vitro: a review.Scandinavian journal of infectious diseases. Supplementum, 74
(1990)
High - performance liquid chromatography of antibiot
A. Hoepelman, H. Kieft, M. Aoun, J. Kosmidis, T. Strand, J. Verhoef, S. Gillespie, J. Riddell, George Varghese, F. Meunier (1993)
International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.The Journal of antimicrobial chemotherapy, 32 Suppl B
H. Aguilar, T. Meredith, A. Shaarawy, M. Kincaid, J. Dick (1995)
VITREOUS CAVITY PENETRATION OF CEFTAZIDIME AFTER INTRAVENOUS ADMINISTRATIONRetina, 15
H. Elkhaïli, L. Linger, Henri Monteil, François Jehl (1997)
High-performance liquid chromatographic assay for cefepime in serum.Journal of chromatography. B, Biomedical sciences and applications, 690 1-2
H. Neu (1996)
Safety of cefepime: a new extended-spectrum parenteral cephalosporin.The American journal of medicine, 100 6A
Mark Okamoto, R. Nakahiro, Alfred Chin, A. Bedikian, Mark Gill (1994)
Cefepime: a new fourth-generation cephalosporin.American journal of hospital pharmacy, 51 4
T. Meredith (1993)
Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.Transactions of the American Ophthalmological Society, 91
F. Jehl, C. Gallion, H. Monteil (1990)
High-performance liquid chromatography of antibiotics.Journal of chromatography, 531
Jean-Claude Pechère, W. Wilson, H. Neu (1995)
Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.The Journal of antimicrobial chemotherapy, 36 5
J. Ferencz, E. Assia, L. Diamantstein, E. Rubinstein (1999)
Vancomycin concentration in the vitreous after intravenous and intravitreal administration for postoperative endophthalmitis.Archives of ophthalmology, 117 8
Dennis Han, S. Wisniewski, L. Wilson, M. Barza, A. Vine, B. Doft, S. Kelsey (1996)
Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study.American journal of ophthalmology, 122 1
W. Craig (1995)
Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.Diagnostic microbiology and infectious disease, 22 1-2
B. Vogelman, W. Craig (1986)
Kinetics of antimicrobial activity.The Journal of pediatrics, 108 5 Pt 2
T. Meredith, H. Aguilar, A. Shaarawy, M. Kincaid, J. Dick, M. Niesman (1995)
Vancomycin levels in the vitreous cavity after intravenous administration.American journal of ophthalmology, 119 6
C. Sanders (1993)
Cefepime: the next generation?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 17 3
P. Shah, W. Junghanns, W. Stille (1976)
Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureusDeutsche Medizinische Wochenschrift, 101
(1996)
Safety of cefepime: A new extendedspectrum cephalosporin antibiotic
F. Jehl, P. Birckel, H. Monteil (1987)
Hospital routine analysis of penicillins, third-generation cephalosporins and aztreonam by conventional and high-speed high-performance liquid chromatography.Journal of chromatography, 413
Purpose: To investigate the penetration of cefepime (a fourth-generation cephalosporin) into the vitreous after single-dose intravenous administration to human subjects. Methods: Thirty phakic patients about to undergo vitreous surgery received 1 g (group 1, 15 patients) or 2 g cefepime (group 2, 15 patients) in a single intravenous injection before surgery. The indications for vitreous surgery were retinal detachment with proliferative vitreoretinopathy (24 patients), retinal detachment associated with giant retinal tear (4 patients), macular hole (1 patient) and intraocular foreign body (1 patient). Samples of vitreous and serum were obtained at 0.5, 1, 2, 4 and 12 h after injection. Three patients were used for each sampling time and for 1 g and 2 g of cefepime. Samples were assayed for cefepime concentrations with high-performance liquid chromatography (HPLC). Results: All the patients had detectable cefepime in their vitreous and serum measurable by HPLC. The level of cefepime in the vitreous peaked at 2 h and reached a minimum at 12 h after intravenous injection in both groups. A mean peak vitreous level of cefepime was 1.91 ± 0.13 µg/ml in group 1 and 2.86 ± 0.37 µg/ml in group 2. The level of cefepime in the vitreous at 12 h after injection was 0.89 ± 0.14 µg/ml in group 1 and 0.97 ± 0.30 µg/ml in group 2. Conclusion: The vitreous level of cefepime after intravenous injection was below the minimum inhibitory concentration (MIC<sub>90</sub>) against Staphylococcus aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa, but was over the MIC<sub>90</sub> against Proteus mirabilis, Klebsiella spp., Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes and Enterobacter spp.
Ophthalmologica – Karger
Published: Aug 1, 2002
Keywords: Intravitreal penetration; Cefepime
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.